There appears to be a clear and direct translational opportunity, which is to use low-dose type-I interferons (IFN-α or IFN-ß, as used for adjuvant therapy of malignancy, in infections and autoimmune conditions) in chronic-refractory pain. Here, IFNA1 is linked to infection.